Financial Performance - The company's revenue for the first half of 2023 was approximately ¥1.34 billion, representing a 1.84% increase compared to the same period in 2022[24]. - Net profit attributable to shareholders was approximately ¥44.22 million, reflecting a 3.04% increase year-over-year[24]. - The company achieved operating revenue of CNY 1,341.62 million in the first half of 2023, an increase of 1.84% year-on-year[54]. - The total revenue for the company reached approximately CNY 257.39 million, with a net profit of CNY 11.83 million[83]. - The company reported a net profit of CNY 39,399,021.62 for the first half of 2023, compared to CNY 22,735,304.56 in the first half of 2022, indicating an increase of about 73.5%[173]. - The total comprehensive income for the first half of 2023 was CNY 39,399,021.62, compared to CNY 22,735,304.56 in the first half of 2022, marking an increase of approximately 73.5%[173]. - The company reported a total comprehensive income of CNY 44.2 million for the current period, reflecting a significant increase compared to the previous period[181]. Cash Flow and Investments - The net cash flow from operating activities decreased by 4.93% to approximately ¥176.94 million compared to the previous year[24]. - The net cash flow from investing activities improved by 78.30%, with a net outflow of ¥13,021,304.78 compared to ¥59,997,551.87 in the previous year[56]. - The net cash flow from financing activities increased by 44.49%, with a net outflow of ¥67,100,234.39 compared to ¥120,874,759.41 in the previous year[56]. - The company’s cash and cash equivalents increased significantly by 1,808.98% to ¥99,946,458.76 from ¥5,235,597.75, driven by improved cash flows from investment and financing activities[56]. - The cash inflow from financing activities totaled 112,393,695.68 CNY, while cash outflow was 98,869,488.27 CNY, resulting in a net inflow[178]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.93 billion, an increase of 1.34% from the end of the previous year[24]. - The company's total liabilities as of the end of the reporting period were CNY 2,550,703,581.39, slightly up from CNY 2,521,932,805.74 at the end of the previous year[168]. - Cash and cash equivalents at the end of the reporting period amounted to ¥780,186,326.51, representing 19.86% of total assets, a decrease of 0.73% compared to the previous year[64]. - Total current assets increased to CNY 2,143,518,721.43 as of June 30, 2023, up from CNY 2,045,284,627.03 on January 1, 2023, representing a growth of approximately 4.8%[159]. - The total liabilities of the company were 253 million yuan, which is a 9.29% increase compared to the previous year[186]. Operational Efficiency and Cost Management - The company plans to strengthen cost management and expand into new markets to enhance competitiveness amid industry risks[5]. - The operating cost for the same period was CNY 739.05 million, up 5.04% year-on-year, resulting in a comprehensive gross margin of 44.91%, a decrease of 1.68 percentage points compared to the previous year[54]. - The company plans to enhance operational efficiency by optimizing its industrial layout and reducing operational costs[87]. - The company is focusing on innovative collaborations with channel partners to enhance strategic and capital cooperation[36]. Product Development and Market Expansion - The company is focusing on expanding its product matrix to include adult nutrition products and special medical purpose formula foods[85]. - The company plans to focus on brand building and collaboration to enhance brand awareness and create popular products through various media channels[88]. - The company is exploring strategic partnerships and potential acquisitions to enhance its market presence[181]. - The company has launched the "Ainoda" series of probiotics and lactoferrin nutritional milk powder for adult customers, enhancing its product offerings[36]. Research and Development - Research and development expenses decreased by 34.85% to ¥6,969,869.31 from ¥10,698,461.48, primarily due to the completion of new national standard registrations[56]. - The company aims to enhance its technological capabilities through ongoing research and development initiatives[185]. - The company holds 24 invention patents and has registered 12 infant formula products under the new national standards[48]. Corporate Governance and Compliance - The company has no significant litigation or arbitration matters during the reporting period[113]. - The company has not faced any environmental penalties during the reporting period and adheres to strict environmental management practices[99]. - The company has established a procurement agreement with suppliers and is committed to strengthening internal control systems to ensure compliance and risk management[110]. - The financial report for the first half of 2023 has not been audited[157]. Shareholder Information - No cash dividends or stock bonuses will be distributed to shareholders for this period[9]. - The company did not distribute cash dividends or issue bonus shares for the first half of 2023[94]. - The largest shareholder, Beiyinmei Group, holds 18.19% of the shares, totaling 196,418,500 shares, with 141,850,000 shares pledged and 53,000,000 shares frozen[146]. - The company has repurchased a total of 20,245,991 shares, representing 1.87% of the total share capital, with a total transaction amount of approximately 103.76 million yuan[140].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,317,396,660.52, representing a 17.47% increase compared to CNY 1,121,481,666.83 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 42,914,990.66, up 28.01% from CNY 33,524,658.31 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 27,356,468.67, reflecting a significant increase of 60.08% from CNY 17,088,924.55[24]. - The net cash flow from operating activities surged to CNY 186,103,264.43, a remarkable increase of 412.18% compared to CNY 36,335,620.30 in the previous year[24]. - The basic earnings per share rose to CNY 0.04, marking a 33.33% increase from CNY 0.03[24]. - The total comprehensive income for the first half of 2022 was CNY 43,719,463.40, compared to CNY 40,962,410.80 in the same period of 2021, showing an increase of 4.3%[170]. - The total profit for the first half of 2022 was CNY 48,870,125.87, a decrease from CNY 50,277,651.93 in the same period of 2021, reflecting a decline of 2.8%[170]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,079,980,580.69, a slight increase of 0.26% from CNY 4,069,421,166.85 at the end of the previous year[24]. - The company's total liabilities amounted to CNY 2,669,442,398.12 as of June 30, 2022, compared to CNY 2,519,631,052.61 at the start of the year, indicating an increase of 5.9%[166]. - The total equity attributable to shareholders reached CNY 2,116,247,124.94, up from CNY 2,092,842,220.38 at the beginning of the year, reflecting a growth of 1.1%[166]. - The company's cash and cash equivalents increased to CNY 793,428,330.71 from CNY 676,870,643.54, representing a growth of approximately 17.3%[160]. - The company's total liabilities decreased to CNY 1,785,836,479.80, indicating improved financial stability[181]. Revenue Segments - The sales revenue of children's powder increased by 286% year-on-year, while the sales of special medical formula milk powder grew by over 62.40%[37]. - Revenue from the milk powder segment was ¥1,190,471,160.39, accounting for 90.37% of total revenue, with a year-on-year growth of 18.20%[59]. - The gross profit margin for the main business was 48.55%, with a year-on-year increase of 16.44%[41]. - The gross profit margin for the infant industry was 46.59%, a decrease of 7.01% compared to the previous year[60]. Investments and R&D - The company has established six infant formula production plants and has implemented advanced management systems including MES, WMS, and ERP to enhance production efficiency[49]. - The company holds 21 invention patents and has registered 60 infant formula products, showcasing its strong R&D capabilities in the industry[48]. - Research and development expenses decreased by 28.95% to CNY 10,698,461.48, reflecting a strategic focus on cost management[55]. - The company’s R&D expenses decreased to CNY 1,320,345.28 in the first half of 2022 from CNY 348,945.37 in the previous year, indicating a significant increase in investment in innovation[172]. Market and Sales - The number of distributors increased from 1,526 at the end of 2021 to 1,685 by June 2022, marking a growth rate of 10%[42]. - The company’s e-commerce sales accounted for 16.83% of total revenue, with a year-on-year growth of 12.48%[41]. - The company launched new products including "Aijia Organic A2" and "Aijia Baohu Cover" series infant formula during the reporting period[39]. Corporate Governance and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[5]. - The company has implemented measures to enhance regulatory compliance and prevent related party investment issues[134]. - The company has not reported any issues or other situations regarding the use and disclosure of raised funds[79]. Future Outlook - The company plans to continue expanding its product offerings and market presence, focusing on innovation and strategic partnerships[63]. - Future guidance and performance outlook remain optimistic, with a focus on enhancing shareholder value[145]. - The company plans to continue focusing on improving its financial health and exploring new market opportunities in the upcoming quarters[200].

Financial Performance - The company's operating revenue for 2021 was ¥2,345,458,993.11, a decrease of 11.99% compared to ¥2,665,134,436.24 in 2020[21] - The net profit attributable to shareholders in 2021 was ¥73,314,574.33, a significant increase of 122.61% from a loss of ¥324,279,930.45 in 2020[21] - The net cash flow from operating activities reached ¥246,743,802.53, representing a remarkable increase of 713.34% compared to ¥30,336,940.67 in 2020[21] - Basic earnings per share for 2021 were ¥0.07, a turnaround from a loss of ¥0.32 per share in 2020, marking a 121.88% improvement[21] - The total assets at the end of 2021 were ¥4,069,421,166.85, reflecting a slight increase of 0.87% from ¥4,034,293,142.99 at the end of 2020[21] - The weighted average return on equity improved to 4.78% in 2021, up by 25.70% from -20.92% in 2020[21] - The net profit after deducting non-recurring gains and losses was ¥7,296,140.06, compared to a loss of ¥481,509,592.22 in 2020, indicating a 101.52% increase[21] - The total operating revenue for the fourth quarter reached ¥687,390,826.59, with a total annual revenue of ¥2,345,458,993.11, showing a consistent performance across the quarters[26] - The net profit attributable to shareholders for the fourth quarter was ¥34,564,672.37, while the annual net profit was ¥73,309,574.33, indicating a recovery trend[26] - The net cash flow from operating activities in the fourth quarter was ¥154,918,757.64, significantly higher than the previous quarters, reflecting improved operational efficiency[26] Business Strategy and Market Position - The company is positioned among the top 20 enterprises in China's dairy industry, emphasizing its commitment to high-quality product offerings and consumer satisfaction[34] - The company has completed a full industry chain layout, integrating research, production, and sales, which enhances its competitive edge in the market[34] - The company is transitioning towards a new retail business model, achieving preliminary results in this strategic shift[34] - The government policies promoting dairy industry revitalization and consumer health awareness are expected to benefit the company's growth in the long term[33] - The company maintains a strong brand image and customer loyalty, which are crucial for sustaining its market position in the infant formula sector[34] - The company launched several new products in 2021, including "Ke Ruixin" infant formula and "Jingcai" series nutritional products, expanding its product matrix significantly[40] - The company’s ODM and OEM business has been actively expanded to optimize industrial structure and improve capacity utilization[41] - The company aims to strengthen its main product categories and expand into niche markets by optimizing product structure and enhancing user lifecycle management[97] - The company is focusing on building a reputation through user-generated content and KOL partnerships to enhance brand credibility[97] - The company is positioned to capitalize on the growing demand for healthy food products, particularly in the context of increasing consumer awareness about nutrition[124] Financial Management and Governance - The company reported a significant increase in financial expenses by 69.84% to ¥74,994,949.41, mainly due to increased exchange losses[68] - The company’s R&D expenses increased by 113.12% year-on-year, amounting to ¥26,135,300.31, primarily due to increased investment in formula registration research[68] - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, aligning with legal regulations[111] - The company operates independently from its controlling shareholder in terms of business, personnel, assets, organization, and finance, ensuring complete operational autonomy[114] - The company’s governance structure aligns with the regulations set forth by the China Securities Regulatory Commission, with no significant discrepancies identified[113] - The company has committed to maintaining high standards in corporate governance with a well-structured board and management team[125] - The company is focusing on improving its financial management practices following regulatory feedback to enhance transparency and accuracy in reporting[130] Employee and Management Changes - The company reported a resignation of the former General Manager, Bao Xiufei, due to personal reasons on January 14, 2021[120] - The company experienced a change in its board with Director Xu Liangjun resigning on January 21, 2021, due to work-related reasons[120] - The company noted the resignation of Vice General Manager Wang Yunfang on February 9, 2021, also due to personal reasons[120] - The company’s independent director Ma Juan and director Li Jun left the board on May 21, 2021, as their term expired[120] - The company’s Vice General Manager and Chief Financial Officer Chen Bin resigned on December 22, 2021, for personal reasons[120] - The company reported a significant leadership change with the appointment of Xie Hong as both Chairman and General Manager on May 21, 2021, following the resignation of several key executives[121] - The company has seen changes in its financial management team, with the appointment of Jin Zhiqiang as the new Financial Director on December 22, 2021, reflecting a commitment to financial oversight[123] Social Responsibility and Environmental Initiatives - The company has established a comprehensive environmental management system, ensuring pollutant emissions are within regulatory limits and has not faced any environmental penalties during the reporting period[168] - The company donated 2,000 boxes of formula milk worth over 1.87 million yuan to improve local children's nutrition in Guizhou Province[169] - The company actively participated in social responsibility initiatives, including support for families with multiple births and special needs children[169] - The company emphasizes the harmonious unity of five values: customer value, employee value, shareholder value, partner value, and social value[170] - The company has implemented measures to manage carbon emissions and promote clean production practices[168] - The company has committed to continuous improvement of its corporate governance and operational standards in response to regulatory requirements[166] Related Party Transactions and Legal Matters - The company is involved in two major lawsuits with total amounts of 1,174.38 million yuan, with ongoing court proceedings[186] - The company’s controlling shareholder, Beiyinmei Group, had 4,466,576 shares frozen by the court, representing 2.10% of its total shareholding due to a dispute[188] - The company reported a related party transaction amounting to 8,125.3 million yuan for raw material procurement, which accounted for 6.22% of the total transaction amount[189] - The company has engaged in various related party transactions, including a procurement agreement with its parent company for 1,962.3 million yuan[190] - The company is actively taking measures to resolve the financial disputes with Zhejiang Construction Group[188]

Financial Performance - Q3 2023 revenue was CNY 574,488,123.09, a decrease of 2.98% year-over-year, while year-to-date revenue reached CNY 1,916,107,983.63, an increase of 0.35%[4] - Net profit attributable to shareholders for Q3 2023 was CNY 5,146,962.63, a significant increase of 285.62% year-over-year, with year-to-date net profit at CNY 49,364,645.85, up 11.56%[4] - Basic and diluted earnings per share for Q3 2023 remained at CNY 0.0100, unchanged from the previous year, while year-to-date earnings per share increased by 25% to CNY 0.05[4] - The net loss for the period was reduced to ¥1,066,844,935.99 from ¥1,116,209,581.84, reflecting a positive trend in financial performance[25] - The operating profit for the third quarter was CNY 67,429,249.83, compared to CNY 55,114,409.94 in the previous year, marking a 22.2% increase[27] - The company reported a total comprehensive income of CNY 64,168,023.17, compared to CNY 46,634,781.79 in the previous year, indicating a growth of 37.5%[27] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was CNY 297,810,653.72, reflecting a decrease of 2.12%[4] - The cash flow from operating activities generated a net amount of CNY 297,810,653.72, slightly down from CNY 304,272,487.38 in the same quarter last year[29] - The company experienced a net cash outflow from financing activities of CNY -155,321,218.27, an improvement from CNY -304,393,141.30 in the same period last year[30] - The cash and cash equivalents at the end of the period amounted to CNY 748,419,671.44, up from CNY 551,080,662.03 at the end of the previous year[30] - The net increase in cash and cash equivalents for Q3 2023 was CNY 23,103,730, reflecting a growth of 258.95% compared to the same period last year[15] Assets and Liabilities - Total assets at the end of Q3 2023 were CNY 3,883,811,446.16, a slight increase of 0.17% compared to the end of the previous year[4] - Total current assets increased to ¥2,124,436,465.62 from ¥2,045,284,627.03, driven by a rise in inventory to ¥464,175,023.05 from ¥413,034,354.70[23] - Total liabilities decreased to ¥2,234,730,099.12 from ¥2,285,997,270.56, with current liabilities also showing a decline[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 70,880[16] - The largest shareholder, Beiyinmei Group Co., Ltd., holds 18.19% of shares, totaling 196,418,500 shares, with 141,850,000 shares pledged and 53,000,000 shares frozen[16] - The company has repurchased a total of 20,152,268 shares, accounting for 1.87% of the total share capital[17] - The company has not disclosed any relationships or agreements among the top 10 shareholders beyond the known associations[17] - The company’s major shareholders are involved in margin trading, with significant holdings through various securities accounts[17] Investment Activities - Investment income for Q3 2023 increased by 138.38% year-over-year, amounting to an absolute increase of CNY 10,167,500[12] - Cash inflow from investment activities surged by 2501.33% year-over-year, totaling an increase of CNY 47,564,700[13] - The total cash inflow from investment activities was CNY 49,466,257.17, a significant increase from CNY 1,901,572.43 in the previous year[29] - The company reported an investment income of ¥17,515,285.73, significantly higher than ¥7,347,747.28 from the previous period[26] Strategic Developments - The company supports the establishment of an industrial incubation fund by its subsidiary to enhance investment risk management and strategic alignment[18] - As of the announcement date, the company has completed the deregistration of 9 subsidiaries, with additional deregistration processes ongoing[19] - The company is currently undergoing a court-ordered asset freeze of 53,000,000 shares, which represents 26.98% of the shares held by Beiyinmei Group[21] - The company has not completed the registration procedures for the industrial fund as of the announcement date[18] - The company is committed to aligning its development strategy with the interests of all shareholders, particularly minority shareholders[18] Cost Management - Operating costs were reported at ¥1,015,177,849.98, down from ¥1,059,401,474.53, indicating improved cost management[26] - Research and development expenses decreased to ¥12,583,638.60 from ¥14,846,957.14, suggesting a potential shift in investment strategy[26]

Financial Performance - The company's revenue for Q1 2022 was ¥636,322,586.28, representing a 12.25% increase compared to ¥566,858,555.71 in the same period last year[4] - Net profit attributable to shareholders for Q1 2022 was ¥20,126,374.67, a 38.45% increase from ¥14,537,381.04 year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 266.35% to ¥15,517,744.73 from ¥4,235,790.79 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 636,322,586.28, an increase of 12.24% compared to CNY 566,858,555.71 in Q1 2021[24] - Net profit for Q1 2022 reached CNY 20,984,457.67, compared to CNY 18,810,095.29 in Q1 2021, representing an increase of 11.59%[25] Cash Flow - The net cash flow from operating activities increased by 145.02% to ¥52,895,828.43, up from ¥21,588,202.87 in the same quarter last year[4] - The cash inflow from operating activities totaled CNY 709,547,323.73, compared to CNY 631,773,462.88 in Q1 2021, reflecting an increase of 12.34%[27] - The net cash flow from investment activities was -55,799,467.44 CNY, compared to -35,130,372.28 CNY in the previous year, indicating a significant increase in cash outflow[28] - Cash inflow from financing activities totaled 456,813,283.34 CNY, down from 632,522,663.54 CNY year-over-year[28] - The net cash flow from financing activities was -31,319,485.85 CNY, contrasting with a slight positive net flow of 716,698.53 CNY in the previous year[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,112,136,081.48, a 1.05% increase from ¥4,069,421,166.85 at the end of the previous year[4] - The total liabilities as of the end of Q1 2022 amounted to CNY 2,257,924,509.83, slightly up from CNY 2,232,686,402.91 at the end of Q1 2021[21] - The company's cash and cash equivalents increased to CNY 762,081,077.77 from CNY 676,870,643.54, reflecting a growth of approximately 12.6%[19] - Inventory decreased significantly from CNY 505,645,822.70 to CNY 395,590,039.67, a reduction of about 21.8%[19] - Short-term borrowings rose to CNY 1,111,156,125.70, up from CNY 1,011,350,119.07, indicating an increase of approximately 9.9%[20] Shareholder Equity - The equity attributable to shareholders increased by 0.93% to ¥1,802,455,204.51 from ¥1,785,836,479.80 at the end of the last year[4] - The total equity attributable to shareholders of the parent company was CNY 1,802,455,204.51, an increase from CNY 1,785,836,479.80 year-over-year[21] - The company repurchased 8,286,307 shares, accounting for 0.77% of the total share capital[16] Operating Expenses - Operating expenses increased by 21.14% to ¥32,000,000, reflecting the rise in revenue[10] - Total operating costs for Q1 2022 were CNY 595,416,761.88, up from CNY 543,555,353.94 in the same period last year, reflecting a growth of 9.55%[24] - Research and development expenses for Q1 2022 were CNY 4,553,454.36, a slight decrease from CNY 4,754,671.25 in Q1 2021[24] Other Financial Metrics - Basic and diluted earnings per share both doubled to ¥0.02 from ¥0.01 year-over-year[4] - The company experienced a 73.56% reduction in financial expenses, decreasing to ¥426,000 from ¥1,611,000 in the previous year[10] - The company reported a decrease in other comprehensive income after tax of CNY -3,842,449.96 compared to CNY -1,396,328.67 in the previous year[25] - The company has established a joint venture, Yibei Intelligent (Hangzhou) Nutrition Technology Co., Ltd., with a registered capital of CNY 10 million, where the company holds a 40% stake[17] Audit Information - The company did not undergo an audit for the first quarter report[29]

Financial Performance - Revenue for Q1 2023 was CNY 704,386,288.42, an increase of 10.70% compared to CNY 636,322,586.28 in the same period last year[3] - Net profit attributable to shareholders decreased by 39.13% to CNY 12,250,864.35 from CNY 20,126,374.67 year-on-year[3] - Net profit after deducting non-recurring gains and losses fell by 74.40% to CNY 3,972,825.65 compared to CNY 15,517,744.73 in the previous year[3] - Basic and diluted earnings per share both decreased by 50.00% to CNY 0.01 from CNY 0.02 in the same period last year[3] - Total operating revenue for Q1 2023 reached ¥704,386,288.42, an increase of 10.67% compared to ¥636,322,586.28 in the same period last year[27] - Net profit for Q1 2023 was ¥13,837,189.83, a decrease of 34.06% from ¥20,984,457.67 in Q1 2022[28] - The company reported a net profit attributable to shareholders of CNY 17,024,071.02, compared to CNY 16,283,924.71 in the same period last year, reflecting a growth of approximately 4.5%[31] - Total comprehensive income for the period was CNY 18,610,396.50, compared to CNY 17,142,007.71 in the same period last year, showing an increase of approximately 8.5%[31] Cash Flow - Operating cash flow net amount decreased by 55.10% to CNY 23,750,966.73 from CNY 52,895,828.43 year-on-year[3] - The company reported a significant decrease in cash flow from operating activities, with a net cash flow decrease of 55.10% year-on-year[11] - Net cash flow from operating activities was CNY 23,750,966.73, down from CNY 52,895,828.43 in the previous year, indicating a decline of about 55.8%[31] - The company experienced a net cash outflow from investing activities of CNY 14,525,597.70, compared to a net outflow of CNY 55,799,467.44 in the previous year[31] - Cash flow from financing activities resulted in a net outflow of CNY 26,579,720.89, an improvement from a net outflow of CNY 31,319,485.85 in Q1 2022[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,898,115,578.61, a slight increase of 0.54% from CNY 3,877,108,863.41 at the end of the previous year[3] - Current assets totaled ¥2,092,968,469.24, an increase from ¥2,045,284,627.03 at the start of the year[24] - Total liabilities increased to ¥2,304,620,657.89 from ¥2,285,997,270.56 at the beginning of the year[25] - The company's equity attributable to shareholders was ¥1,539,436,575.18, slightly up from ¥1,538,639,572.79 at the beginning of the year[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 75,946[15] - Beiyinmei Group Co., Ltd. holds 18.19% of shares, totaling 196,418,500 shares, with 194,850,000 shares pledged[15] - The company repurchased 28,412,298 shares, accounting for 2.63% of the total share capital[16] - A total of 53,000,000 unrestricted circulating shares held by Beiyinmei Group were frozen, representing 26.98% of its total holdings[19] - The top ten shareholders hold a combined total of 307,000,000 shares, representing a significant portion of the company's equity[15] - The company has not disclosed any related party relationships among the top ten shareholders, except for Beiyinmei Group and Hainan Jinjue Investment Partnership being concerted actors[15] Corporate Actions - The company is in the process of deregistering several subsidiaries, with five already completed[18] - Beiyinmei Group signed a voting rights entrustment agreement, delegating voting rights of 48,000,000 shares, which is 4.44% of the total share capital, to Hainan Jinjue Investment Partnership[20] - The company established a wholly-owned subsidiary in Taizhou, Zhejiang, with a registered capital of 1 million RMB, but the registration has been suspended due to business adjustments[18] - The company plans to support the establishment of an industrial incubation fund by its controlling shareholder, Beiyinmei Group, to enhance investment risk management[17] Financial Position - Cash and cash equivalents net increase rose by 50.84% to CNY 1,739.75 million compared to the same period last year[13] - The company's cash and cash equivalents decreased to ¥787,308,203.43 from ¥798,406,235.96 at the beginning of the year[24] - Accounts receivable decreased to ¥501,382,317.04 from ¥532,681,590.17 at the beginning of the year[24] - The company reported a significant increase in prepayments, which rose to ¥213,416,697.52 from ¥99,029,825.54 at the beginning of the year[24] Audit and Reporting - The company did not undergo an audit for the Q1 2023 report[33] - The report was released by the company's board of directors on January 31, 2024[34]

Revenue and Profitability - Revenue for Q3 2022 reached ¥592,107,666.12, an increase of 10.35% compared to the same period last year[4] - Net profit attributable to shareholders was ¥1,334,719.69, a decrease of 74.46% year-on-year[4] - Net profit excluding non-recurring items was -¥8,578,550.15, an increase of 65.77% compared to the previous year[4] - The company reported a 15.16% increase in revenue year-to-date, totaling ¥1,909,504,326.64[4] - Total operating revenue for the third quarter reached ¥1,909,504,326.64, an increase of 15.1% compared to ¥1,658,068,166.52 in the same period last year[26] - Net profit for the third quarter was ¥47,172,900.31, compared to ¥43,336,196.24 in the previous year, representing an increase of 8.5%[27] - The net profit attributable to the parent company for Q3 2022 was ¥44,249,710.35, an increase from ¥38,749,901.96 in the same period last year, representing a growth of approximately 3.86%[28] - The total comprehensive income for Q3 2022 was ¥46,634,781.79, compared to ¥51,229,088.00 in Q3 2021, indicating a decrease of about 8.93%[28] Cash Flow and Financial Position - Operating cash flow for the year-to-date increased by 231.36% to ¥304,272,487.38[4] - Cash flow from operating activities increased by 24.55% to ¥211,562,000.00 year-on-year[12] - The net cash flow from operating activities for the period was ¥304,272,487.38, significantly up from ¥91,825,044.89 in the previous year, marking an increase of approximately 231.36%[30] - Cash and cash equivalents at the end of Q3 2022 stood at ¥551,080,662.03, down from ¥640,302,877.54 at the beginning of the period, reflecting a decrease of about 13.91%[31] - The total cash inflow from financing activities was ¥821,358,615.03, while the cash outflow was ¥1,125,751,756.33, resulting in a net cash flow from financing activities of -¥304,393,141.30[30] - The net cash flow from investment activities was -¥89,291,451.91, a decrease from ¥239,712,088.55 in the same period last year, indicating a decline of approximately 137.24%[30] Assets and Liabilities - Total assets at the end of the period were ¥3,867,581,511.42, a decrease of 4.96% from the end of the previous year[4] - The company's total assets decreased to ¥3,867,581,511.42 from ¥4,069,421,166.85, a decline of approximately 5%[24] - Current assets totaled ¥1,994,776,202.20, down from ¥2,183,321,715.52, indicating a decrease of 8.6%[24] - Current liabilities decreased to ¥1,964,279,101.59 from ¥2,118,700,258.86, a reduction of 7.3%[24] - Long-term borrowings decreased significantly to ¥23,997,035.01 from ¥65,097,319.44, a decline of 63.2%[24] - The total equity attributable to shareholders increased slightly to ¥1,790,559,595.77 from ¥1,785,836,479.80, reflecting a growth of 0.8%[24] Research and Development - R&D expenses decreased by 39.20% to ¥1,484,000.00 compared to the same period last year[10] - Research and development expenses were ¥14,846,957.14, down from ¥24,418,402.43, indicating a reduction of 39%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 67,614, with no preferred shareholders having restored voting rights[17] - The largest shareholder, Beiyinmei Group Co., Ltd., holds 18.65% of shares, amounting to 201,418,500 shares, with 194,850,000 shares pledged[17] - The company has repurchased a total of 15,758,586 shares, accounting for 1.46% of the total share capital, which are held in a dedicated repurchase account[18] - The company experienced a 69.73% increase in treasury stock, amounting to ¥39,992,900.00 due to share buybacks[8] Strategic Initiatives and Future Outlook - The company supports the establishment of an industrial incubation fund by its wholly-owned subsidiary to enhance the integration of industry and finance, aiming to mitigate investment risks[19] - The company transferred part of its equity in Guangxi Quanan Sheng Enterprise Management Co., Ltd., reducing its stake to 48%, which is no longer included in the consolidated financial statements[20] - The company will calculate financial assistance interest at an annualized rate of 5% based on the actual amount and duration of funds used by Guangxi Quanan Sheng[20] - The company has not disclosed any significant new product or technology developments in the current report[22] - There are no indications of market expansion or mergers and acquisitions mentioned in the current report[22] - The company has not provided specific future performance guidance or outlook in the current report[22] Operating Costs and Profit Margins - Total operating costs amounted to ¥1,832,788,824.10, up from ¥1,567,103,646.91, reflecting a year-over-year increase of 16.9%[27] - The company reported a gross profit margin of approximately 44.5% for the quarter, compared to 52.8% in the previous year[27] - The company reported a basic and diluted earnings per share of ¥0.04, consistent with the previous year[28]

Financial Performance - The company's operating revenue for 2022 was ¥2,509,171,932.67, an increase of 6.98% compared to ¥2,345,458,993.11 in 2021[6]. - The net profit attributable to shareholders was -¥175,996,805.92, representing a decrease of 340.06% from ¥73,314,574.33 in the previous year[6]. - The net cash flow from operating activities increased by 52.96% to ¥377,416,659.60, up from ¥246,743,802.53 in 2021[6]. - The basic and diluted earnings per share were both -¥0.16, a decline of 328.57% compared to ¥0.07 in 2021[6]. - Total assets at the end of 2022 were ¥3,877,108,863.41, a decrease of 4.73% from ¥4,069,421,166.85 at the end of 2021[6]. - The net assets attributable to shareholders decreased by 13.84% to ¥1,538,639,572.79 from ¥1,785,836,479.80 in 2021[6]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, amounting to -¥212,862,617.24 in 2022 compared to ¥7,296,140.06 in 2021[6]. - The gross profit margin for the company was 45.88%, a decrease of 4.93% from the previous year[59]. Market and Product Development - The company plans to enhance market expansion and sales scale while strengthening cost management and expense control to improve competitiveness[5]. - The infant formula market is expected to see increased demand, particularly in lower-tier cities, driven by rising consumer trust in domestic dairy products[43]. - The company is focusing on expanding its product matrix with innovative products like the "珍质系列" and "叶酸龙凤太" to meet consumer needs[43]. - The company completed the registration of 10 key series and 30 products under the new national standards, with ongoing registration for other products[43]. - The company is actively exploring strategic partnerships and collaborations to enhance its ODM and OEM business capabilities[44]. - The company is investing in new technology development, allocating 100 million RMB towards R&D initiatives aimed at enhancing product quality and safety[131]. Corporate Governance and Compliance - The company emphasizes the importance of product quality and safety, implementing advanced detection equipment and technology for comprehensive quality control[7]. - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[5]. - The company is focusing on improving its financial reporting processes to prevent future discrepancies and enhance transparency[136]. - The company has established a performance evaluation and incentive mechanism for senior management to ensure accountability and transparency[119]. - The company has adhered to legal regulations and internal rules in fulfilling board responsibilities[145]. - The company received an unqualified audit report with an emphasis of matter paragraph from Da Hua Accounting Firm for the fiscal year 2022, indicating that the report reflects the company's financial situation accurately[188]. Social Responsibility and Community Engagement - The company donated over 2.6 million yuan to various charitable organizations during the reporting period, supporting initiatives for special needs infants and families[174]. - The company has been actively involved in social responsibility initiatives, including the "Love Baby Project," "育婴工程" (Child Rearing Project), and "亲母工程" (Mother Care Project) since its inception[175]. - The company has established a comprehensive social welfare system to support the healthy growth of children and promote scientific parenting knowledge[175]. Strategic Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 12% based on market trends and new product launches[109]. - The company is actively pursuing market expansion strategies, targeting a 25% increase in distribution channels by the end of 2023[109]. - The company plans to focus on the adult nutrition market and accelerate the research and industrialization of special medical purpose formula foods[104]. - The company is considering strategic acquisitions to enhance its supply chain efficiency, with a budget of 200 million RMB earmarked for potential mergers[131]. Operational Efficiency - The company aims to improve asset liquidity by enhancing accounts receivable collection and fine-tuning asset management[6]. - The company has implemented a digital retail platform to enhance market reach and consumer interaction[54]. - The company operates six dairy processing plants and has established advanced management systems including MES, WMS, and ERP[52]. - The company has allocated CNY 33 million for working capital, with an investment of CNY 7.57 million, achieving a completion rate of 100.11%[96]. Employee Management and Compensation - The total number of employees at the end of the reporting period was 2,095, with 1,020 in the parent company and 1,075 in major subsidiaries[152]. - The company emphasizes performance-based compensation, linking employee performance pay to both individual and company performance[153]. - The company established a new compensation plan for senior management, ensuring that salaries were fully disbursed according to the approved scheme[139]. - The employee stock ownership plan included 200 employees holding a total of 2,480,000 shares, representing 0.23% of the company's total equity[160]. Risk Management - The company is focused on risk management, particularly in industry, financial, and food safety risks[5]. - The company has committed to enhancing internal control measures and risk awareness among relevant personnel following the identified issues[186]. - The company reported a supplier receivable of CNY 81,105,500 due to inadequate background checks and management of advance payments, with CNY 735,690 received before the report issuance[185]. Environmental Responsibility - The company’s important production subsidiaries are not listed as key pollutant discharge units according to local environmental authorities[173][174]. - The company has received certifications for clean production, energy management, and environmental management systems, ensuring compliance with environmental regulations[173].

证券代码：002570 证券简称：贝因美 公告编号：2024-015 贝因美股份有限公司 第八届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由贝因美股份有限公司（以下简称"公司"或"贝因美"） 董事长谢宏先生召集和主持，会议通知于 2024 年 1 月 22 日以邮件方式发出。 2、本次董事会于 2024 年 1 月 30 日召开，采用现场、通讯相结合的方式召 开、表决。 3、本次董事会应出席董事 8 人，实际参与表决董事 8 人。公司监事、高级 管理人员列席了会议。 4、本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规 和《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于注销部分子公司的议案》。 2013年2月5日，公司第五届董事会第六次会议审议通过了《关于在爱尔兰投 资设立全资子公司的议案》。2013年11月25日，公司第五届董事会第十四次会议 审议通过了《关于调整在爱尔兰设立全资子公司方案的议案》，公司全资子公司 北海贝因美营养食品有限公司拟 ...

贝因美股份有限公司 前期会计差错更正专项说明的审核报告 大华核字[2024]0011000344 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） ［右键单击上一行首，选择更新域键入公司名称的全称］ ［右键单击上一行首，选择更新域键入公司名称的简称］ 贝因美股份有限公司 前期会计差错更正专项说明的审核报告 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 前期会计差错更正专项说明的审核报告 1-2 二、 贝因美股份有限公司前期会计差错更正专项 说明 1-4 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 前期会计差错更正专项说明的 审核报告 大华核字[2024]0011000344号 贝因美股份有限公司全体股东： 我们接受委托，审核了后附的贝因美股份有限公司（以下简称 "贝 ...